Interpretation of Global Allergy and Asthma European Network Anaphylaxis Centres of Reference and Exce-llence consensus statement: potential of Omalizumab in food allergy management
10.3760/cma.j.cn101070-20241227-00875
- VernacularTitle:全球过敏与哮喘欧洲网络严重过敏反应中心关于食物过敏管理中奥马珠单抗潜力的专家共识解读
- Author:
Peng HAN
1
;
Shanshan LIU
;
Jingjing QIAO
;
Kunling SHEN
Author Information
1. 深圳市儿童医院呼吸科，深圳 518038
- Publication Type:Journal Article
- Keywords:
Food allergy;
Immunoglobulin E;
Anaphylaxis;
Omalizumab
- From:
Chinese Journal of Applied Clinical Pediatrics
2025;40(3):176-179
- CountryChina
- Language:Chinese
-
Abstract:
The incidence of food allergy is on the rise, with the capacity to impact various organ systems, including but not limited to the skin, respiratory system, gastrointestinal system, cardiovascular system, and nervous system.In extreme cases, these allergies can result in anaphylaxis.Immunoglobulin E (IgE)-mediated type Ⅰ hypersensitivity reactions are a common cause of food allergy and are the primary pathway to anaphylaxis.Omalizumab, the first biologic therapy approved for the treatment of IgE-mediated food allergy, can be incorporated into a comprehensive management strategy for food allergy sufferers.However, due to the lack of definitive evidence, the safety and efficacy of Omalizumab in all patients with IgE-mediated food allergy remain equivocal.In light of this, Global Allergy and Asthma European Network Anaphylaxis Centres of Reference and Excellence convened a panel of experts to deliberate on the appropriate patient and therapeutic strategies for Omalizumab, culminating in a consensus statement.This paper aimed to interpret the consensus proposed by the experts, with the objective of assisting clinicians in better understanding the application of Omazumab in patients with IgE-mediated food allergy.
